Harrow, Inc. (NASDAQ:HROW) Shares Sold by Royce & Associates LP

Royce & Associates LP lessened its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 18.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 292,090 shares of the company's stock after selling 68,230 shares during the period. Royce & Associates LP owned 0.82% of Harrow worth $9,800,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of HROW. Quest Partners LLC purchased a new position in Harrow in the third quarter worth approximately $29,000. AlphaQuest LLC grew its holdings in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after purchasing an additional 2,889 shares during the period. Virtu Financial LLC acquired a new stake in shares of Harrow during the 3rd quarter worth about $271,000. Principal Financial Group Inc. purchased a new stake in Harrow in the 3rd quarter valued at about $329,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Harrow in the 3rd quarter valued at about $338,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Up 1.1 %

HROW traded up $0.32 on Friday, hitting $28.41. 625,226 shares of the company were exchanged, compared to its average volume of 495,368. The firm has a 50-day moving average price of $29.51 and a two-hundred day moving average price of $38.40. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a twelve month low of $9.86 and a twelve month high of $59.23. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -30.22 and a beta of 0.69.

Remove Ads

Analyst Upgrades and Downgrades

HROW has been the subject of a number of recent analyst reports. B. Riley dropped their price target on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research report on Wednesday, December 4th. HC Wainwright reiterated a "buy" rating and issued a $57.00 target price on shares of Harrow in a report on Tuesday.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.